comprehensive -WSS

comprehensive

author：fashion 2025-09-05 05:07:12 - browse：81387

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Elevance PBM president out as customers face prescription chaos

WSS

How the messy conversation about Dolly changed bioethics

Assistant physicians can help address the primary care shortage

Eli Lilly CEO gives to Mike Pence presidential super PAC

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Midwives could help bridge maternal health disparities in the U.S.

ASCO Daily Recap: CAR

hotspot

comprehensive

focus

BioMarin wins approval for gene therapy to treat hemophilia A

FTC loses bid to block Novant's North Carolina hospital merger

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Eli Lilly’s Zepbound improved liver scarring in mid

Activists slam private health insurers over coverage restrictions

Fed up with FDA, ALS advocates consider a take

Bright Health sells Medicare Advantage business to Molina

Transgender sports debate: Physicians say bans are health issue

Affirmative action in medical school literally saved lives

Structure Therapeutics oral GLP

entertainment

Assistant physicians can help address the primary care shortage

Why the quest to eradicate polio has stumbled

BD to buy Edwards patient monitoring unit for $4.2 billion

PBMs drew scrutiny in House hearing — and so did pharma

Information blocking fines are now fair game in health care

A new initiative will help leaders fight the next pandemic

entertainment

Wikipedia

hotspot

focus